Technology | Digital Pathology | May 29, 2019

Leica Biosystems Receives FDA Clearance for Aperio AT2 DX Digital Pathology System

Digital pathology system cleared for primary diagnosis following multi-center study at five clinical sites in the U.S.

Leica Biosystems Receives FDA Clearance for Aperio AT2 DX Digital Pathology System

May 29, 2019 — Leica Biosystems has received clearance from the U.S. Food and Drug Administration (FDA) to market its Aperio AT2 DX System for clinical diagnosis in the U.S.

A multi-center study supporting this clearance was conducted with pathologists at five clinical study sites in the U.S.:

  • University of California Davis;
  • Pacific Rim Pathology;
  • Dignity Health;
  • TriCore Reference Laboratories; and
  • Intermountain Healthcare.

One of the largest clinical concordance studies ever completed on digital whole slide images, the participating pathologists read approximately 16,000 cases. The study compared reads of pathology slides under a microscope with on-screen digital reads.  

The Aperio AT2 DX System is a high-throughput automated scanning and viewing platform. The platform will be launched commercially with clinical image management software for an integrated digital pathology workflow solution.

For more information: www.leicabiosystems.com

Related Content

Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
Xifin Launches Version 6 of Laboratory Information System
News | Digital Pathology | September 05, 2019
Xifin announced the launch of the next evolution of its laboratory information system (LIS), Xifin LIS 6. The expanded...
News | Contrast Media | September 03, 2019
Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast...
An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart. #ASTRO19 #ASTRO2019 #ASTRO

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart.

Feature | ASTRO | August 29, 2019
August 29, 2019 — The American Society for Radiation Oncology (ASTRO) announced th
FDA Encourages Inclusion of Male Patients in Breast Cancer Clinical Trials
News | Women's Health | August 26, 2019
The U.S. Food and Drug Administration (FDA) released a new draft guidance that encourages including male patients in...
Moffitt Researchers Develop Model to Personalize Breast Cancer Radiation Treatment
News | Radiation Therapy | August 26, 2019
A personalized approach to cancer treatment has become more common over the last several decades, with numerous...